OB/GYN Clinical Alert – December 1, 2017
December 1, 2017
View Issues
-
New Treatment Option for Women at Risk of Fragility Fractures
A randomized trial demonstrated a reduced risk of fragility fractures in high-risk women with osteoporosis treated monthly with the monoclonal antibody romosozumab compared with weekly alendronate.
-
Trends in OB/GYN Malpractice Litigation
In this review of medicolegal claims data from 2005-2014, obstetric and gynecologic surgery had the second highest average indemnity payment compared to other specialties, topped only by neurosurgery. Of the 10,915 claims identified, the majority (60%) were dropped, withdrawn, or dismissed; 31.1% of claims were paid by the defendant (90% before trial); and 7.5% were successfully defended by the physician.
-
Hormone Replacement: Have We Made Progress Since WHI?
Vaginal estrogen may improve vaginal symptoms of menopause and does not increase the risk for endometrial cancer, stroke, or cardiovascular disease.
-
Update on Postpartum Hemorrhage
In the United States, postpartum hemorrhage accounts for 11.4% of maternal deaths, the fourth most common cause after cardiovascular diseases, non-cardiovascular diseases, and infection; worldwide, it is the leading cause of maternal mortality. This feature will discuss the latest treatments for managing postpartum hemorrhage.